HomeCompareSRRA vs GBDC

SRRA vs GBDC: Dividend Comparison 2026

SRRA yields 3.64% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.82M in total portfolio value
10 years
SRRA
SRRA
● Live price
3.64%
Share price
$54.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$459.50
Full SRRA calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — SRRA vs GBDC

📍 GBDC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSRRAGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SRRA + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SRRA pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SRRA
Annual income on $10K today (after 15% tax)
$309.15/yr
After 10yr DRIP, annual income (after tax)
$390.58/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,982,733.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SRRA + GBDC for your $10,000?

SRRA: 50%GBDC: 50%
100% GBDC50/50100% SRRA
Portfolio after 10yr
$10.44M
Annual income
$8,225,596.67/yr
Blended yield
78.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

SRRA
No analyst data
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SRRA buys
0
GBDC buys
0
No recent congressional trades found for SRRA or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSRRAGBDC
Forward yield3.64%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$25.3K$20.85M
Annual income after 10y$459.50$16,450,733.83
Total dividends collected$4.1K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: SRRA vs GBDC ($10,000, DRIP)

YearSRRA PortfolioSRRA Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$11,064$363.70$12,492$1,791.70$1.4KGBDC
2$12,214$376.07$16,527$3,160.58$4.3KGBDC
3$13,457$388.01$23,588$5,904.90$10.1KGBDC
4$14,799$399.53$37,141$11,901.65$22.3KGBDC
5$16,245$410.62$66,205$26,463.38$50.0KGBDC
6$17,804$421.26$137,452$66,612.65$119.6KGBDC
7$19,481$431.47$342,372$195,298.53$322.9KGBDC
8$21,286$441.25$1,053,292$686,954.33$1.03MGBDC
9$23,227$450.59$4,111,439$2,984,416.95$4.09MGBDC
10$25,312$459.50$20,849,974$16,450,733.83$20.82MGBDC

SRRA vs GBDC: Complete Analysis 2026

SRRAStock

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.

Full SRRA Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this SRRA vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SRRA vs SCHDSRRA vs JEPISRRA vs OSRRA vs KOSRRA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.